Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous BMMNCs in Spinal Cord Injury
NCT02009124Phase 2Withdrawn
- Sponsor
- NeuroGen Brain & Spine Institute
- Start
- Aug 2012
- Primary completion
- Jun 2018
- Countries
- 1
01
Overview
A Phase 2 trial of autologous bone marrow-derived mononuclear cell in spinal cord injury (SCI), sponsored by NeuroGen Brain & Spine Institute. Planned start Aug 2012; status: withdrawn.
02
Drugs
autologous bone marrow-derived mononuclear cell
03
Conditions
spinal cord injury (SCI)
Beyond the preview
Go deeper on NCT02009124.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02009124.